[
  {
    "ts": "2026-02-08T09:27:31+00:00",
    "headline": "Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data […]",
    "url": "https://finance.yahoo.com/news/abbott-laboratories-abt-short-term-092731184.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3783310d-42b3-328b-b662-b981b1d1c6c5",
      "content": {
        "id": "3783310d-42b3-328b-b662-b981b1d1c6c5",
        "contentType": "STORY",
        "title": "Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating",
        "description": "",
        "summary": "Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data […]",
        "pubDate": "2026-02-08T09:27:31Z",
        "displayTime": "2026-02-08T09:27:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3774069e75160f3491e217a8adc68902",
          "originalWidth": 580,
          "originalHeight": 387,
          "caption": "Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6RCH8PBlviwVdgmKACcLw--~B/aD0zODc7dz01ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3774069e75160f3491e217a8adc68902.cf.webp",
              "width": 580,
              "height": 387,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jo4VFE.womibB84sqffwDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3774069e75160f3491e217a8adc68902.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-laboratories-abt-short-term-092731184.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-laboratories-abt-short-term-092731184.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]